Yang, Fang Yang, Yawei Li, Pei Lin, Ke Chen, Lili Dong, Lihua Cao, Yong Tao, Lingtong Hao, Qingjian Chen, Qiang Gong, Dafei Wu, Wenjie Li, Wenming Zhao, Xiuyun Tian, Chunyi Hao, Eric A. Hungate, Daniel V.T. Mark Applebaum, MD, is an expert in pediatric cancers and blood diseases. Dr. Daniel Catenacci, MD, is an Internal Medicine specialist practicing in Chicago, IL with 19 years of experience. Ralph Weichselbaum, Blas Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga . Dr. Daniel Catenacci, MD is a Medical Oncology Specialist in Chicago, IL. Open for more information, UChicago Medicine Medical Group FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in. Catenacci, Theodore Karrison, Jaclyn D Peterson, Mark M. Zalupski, Amikar Sehdev, James L. Wade, Ahad Ali Sadiq, Vincent J. Picozzi, Andrea Amico, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma, Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Sara Kochanny, Kelly Moore, Smita S. Joshi, Stacie Landron, Julie K. Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, R.B. . Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Pinned Tweet. He attended medical school at Wayne State University in Detroit. An arraignment was scheduled for Jan. 4 before U.S. Magistrate Judge Maria Valdez, court records show. Catenacci, Wei-Li Liao, Lei Zhao, Emma Whitcomb, Les Henderson, Emily O'Day, Peng Xu, Sheeno Thyparambil, David Krisman, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, Fabiola Cecchi, Adele Blackler, Yung-Jue Bang, John Hart, Shu-Yuan Xiao, Sang Mee Lee, Jon Burrows, Todd Hembrough, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Fadi S. Dahdaleh, Scott K. Sherman, Elizabeth Poli, Janani Vigneswaran, Blase N. Polite, Manish R. Sharma, Daniel V.T. Catenacci, Mark Kozloff, Hedy L. Kindler, Blase N. Polite, Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic, Thomas Stricker, Daniel V.T. If this issue persists, please contact the University of Chicago Medicine. Treatment of Advanced Gastroesophageal Cancer: A Focus on Targeted Therapies - JACOB phase III Clinical Trial Investigators Meeting: A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and Case Presentation and Review of the literature.. Washington D.C., Dec. 20, 2021 . Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. Following this, Dr Catenacci held positions at . As a clinical investigator, Dr. Rosenberg focuses on developing novel therapeutic strategies, including immunotherapy, for patients with head and neck cancer and thyroid cancer. Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations. Dr. Catenacci purchased more than 8,000 shares before the company . Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. Catenacci, Ronan Fougeray, Shanti Moreno, P. Azcue, H.-T. Arkenau, M. Alsina, David H. Ilson, A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer, Frederick P. Rivara, Steven M. Bradley, Daniel V.T. Novel Targeted Therapies for Esophagogastric Cancer. We offer online appointment scheduling for video and in-person appointments for adult and pediatric primary care and many specialties. She went to medical school at Wayne State University in Detroit and then moved to Ohio for post-graduate training. Looking for something else? Catenacci, Leah Chase, Samantha Lomnicki, Theodore Karrison, Robert de Wilton Marsh, Murtuza Rampurwala, Sunil Narula, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, Bryan Peterson, Kelly Moore, Kristin Kipping-Johnson, Ugne Markevicius, Barbara Gordon, Kenisha Allen, Christine Racette, Steven Brad Maron, Chih-Yi Liao, Blase N. Polite, Hedy L. Kindler, Kiran K. Turaga, Vivek N. Prachand, Kevin K. Roggin, Mark K. Ferguson, Mitchell C. Posner. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Schrock, A. B.,Ouyang, C.,Sandhu, J.,Sokol, E.,Jin, D.,Ross, J. S.,Miller, V. A.,Lim, D.,Amanam, I.,Chao, J.,Catenacci, D.,Cho, M.,Braiteh, F.,Klempner, S. J.,Ali, S. M.,Fakih, M. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Dr. Daniel Catenacci, 45, was charged in a criminal information filed in U.S. District Court with one count of securities fraud, which carries a potential 20 years in federal prison. Catenacci, Howard S. Hochster, Samuel J. Klempner. Sharma MR, Catenacci DVT, Karrison TG, Marsh RW, Kozloff M, Allen K, Polite BN, Kindler HL, T Hembrough, L Henderson, B Rambo, WL Liao, S Thyparambil, K Bengali, J Uzzell, M Darfler, D Krizman, P Xu, S-Y Xiao, L Zhao, J Burrows, DV Catenacci. Daniel Catenacci was a lead physician and investigator for a Phase 2 trial of a stomach . Next-generation companion diagnostics: promises, challenges, and solutions. Dr. Communicate with your doctor, view test results, schedule appointments and more. Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. In November 2020, as the company was readying to publicly announce positive results from the trial, Catenacci secretly purchased more than 8,000 shares in Company A securities, according to the charges. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Her2 expression in Gastroesophageal Cancer (GEC) FFPE Tissue using Mass Spectrometry (MS) and correlation with HER2 gene amplification. (pts) with pancreatic adenocarcinoma (PC). Dr. Daniel Catenacci is a hematologist / oncologist in Chicago. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. He previously received a K23 career development award from the National Cancer Institute. The University Of Chicago Kovler Diabetes Center 900 E 57th St Chicago, IL 60637. Gastroesophageal Adenocarcinoma in The Era of Targeted Therapies: A Focus on MET. Catenacci, 45, an oncologist and director of the gastrointestinal oncology program at the University of Chicago, was a consultant for Five Prime and worked as a clinical investigator . Dr. Catenacci has extensive experience in Pancreatic Neoplasms and Gastrointestinal Neoplasms. Catenacci has held positions at the University of Chicago Medicine for over 15 years, starting as a fellow in Hematology and Medical Oncology from 2006 to 2010. Catenacci, MD, of the University of Chicago Medical Center and Biological Sciences, emphasized the value of the patient having microsatellite instability-high (MSI-H) status as a biomarker for immunotherapy. THE UNIVERSITY OF CHICAGO MEDICAL CENTER - (Acute Care) 5841 SOUTH MARYLAND CHICAGO, IL 60637 1 A sole proprietor/sole proprietorship is an individual, and as such, is eligible for a single NPI number. 3.3 (9 ratings) Catenacci, Daniel D. Von Hoff, Carlos Becerra, Nancy Whiting, Jing Yang, Brian M. Wolpin, A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma, Andrew H. Ko, Noelle K. LoConte, Margaret A. Tempero, Evan J. Walker, R. Kate Kelley, Stephanie Lewis, Wei-Chou Chang, Emily Kantoff, Michael W. Vannier, Daniel V.T. Dr. Daniel Catenacci, MD, director of the Gastrointestinal Oncology Program at the University of Chicago, discusses data from Astellas' Phase 2 FAST study, which evaluated zolbetuximab, an investigational first-in-class anti-CLDN18.2 monoclonal antibody, in combination with first-line epirubicin, oxaliplatin, and capecitabine (EOX) in patients with advanced gastric cancer. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. (GEA) were resoundingly negative. Dr Catenacci, from the Department of Medicine, Section of Hematology/Oncology, at the University of Chicago, in Illinois, told Medscape Medical News that the approach of matching a drug to a . There was an error while submitting your request. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. . Catenacci, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do Youn Oh, Efrat Dotan, Daniel V.T. Where is Dr. Daniel Catenacci, MD's office located? Sign up for our Newsletter Enter your email. Developmental Therapeutics in Oncology: Updates from ASCO 2011 Best of ASCO Meeting. Dr Catenacci obtained his MD from Wayne State University School of Medicine, Detroit, MI after which he completed a residency in internal medicine as the University of California, Los Angeles, CA. Daniel V.T. Perioperative Therapy for Gastroesophageal Adenocarcinoma. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. Find other locations and directions. A more widely used route ran up the western branch of the Holland River, over the moraine . They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. "Tumor molecular heterogeneity, molecular evolution, and implications in the clinic". vero beach soccer tournament 2022; vanderbilt autism evaluation Menu. Biliary cancer: Utility of next-generation sequencing for clinical management. Catenacci DVT, Xu P, Henderson L, Liao WL, Burrows J, Hembrough T. Development of a quantitative colorectal cancer SRM assay for use in FFPE tumor tissues. "Next-Generation Clinical Trials Incorporating Next-Generation Companion Diagnostics". MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Catenacci, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study, Yung Jue Bang, Yoon-Koo Kang, Daniel V.T. Catenacci, Hyun Cheol Chung, Zev A. Wainberg, Michael K. Gibson, Keun Wook Lee, Johanna C. Bendell, Crystal S. Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon Rebelatto, Philip Z Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M. Englert, Geoffrey Y. Ku, Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy, Aparna Raj Parikh, Yuting He, Ted S. Hong, Ryan B. Corcoran, Jeffrey W. Clark, David P. Ryan, Lee Zou, David T. Ting, Daniel V.T. Toward personalized treatment of advanced biliary tract cancers. (773) 702-2371. Catenacci, Drew W. Rasco, Jeeyun Lee, Sun Young Rha, Keun-Wook Lee, Yung-Jue Bang, Johanna C. Bendell, Peter C. Enzinger, Neyssa Marina, Hong Xiang, Wei Deng, Janine Powers, Zev A. Wainberg, Evaluation of the Association of Perioperative UGT1A1 GenotypeDosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial, Daniel V.T. Mark Applebaum. Get a Second Opinion. Catenacci is an associate professor of medicine and oncologist, according to his LinkedIn profile and biography on the University of Chicago's Web site. Let us know if this information is out of date or incorrect. ACR Appropriateness Criteria Staging and Follow-Up of Esophageal Cancer. He is affiliated with The University Of Chicago Medical Center. Catenacci, Sarit Schwartz, Shankar Sellappan, Yuan Tian, Rosalba Miceli, Alessandro Pellegrinelli, Elisa Giommoni, Enrico Aitini, Francesca Spada, Gerardo Rosati, Alberto Marchet, Francesca Pucci, Alberto Zaniboni, Stefano Tamberi, Tiziana Pressiani, Gianni Sanna, Maurizio Cantore, Stefania Mosconi, Paola Bolzoni, Carmine Pinto, Lorenza Landi, Hector Soto Parra, Luigi Cavanna, Salvatore Corallo, Antonia Martinetti, Todd Hembrough, Filippo Pietrantonio. Share Save. Dr. Schell joins AFCC's renowned endocrinology team, which is spearheaded by Dr. Michelle Catenacci, Medical Director. Tumor Board: Management of Challenging Cases of Upper Gastrointestinal Cancers (ARS)" (Invited Panelist), Tumors to the Liver: Metastatic Adenocarcinoma of Unknown Origin Work up before Therapy and Role of Molecular Profiling to Sort it out, Does Molecular Profiling Predict Response to Therapy?, "Tumor Genomics, Immunotherapy, Clinical Trials, and Other Hopes for the Future. (Committee Chair and Organizer, Moderator, Speaker). This work was supported by a National Institutes of Health K12 award (CA139160-01A), University of Chicago Comprehensive Cancer Center Award in Precision Oncology, and LLK Foundation Award (Dr Catenacci). A safety and Feasibility trial. Catenacci, Richard R. Hudson, Wen-Hsiung Li, Xuemei Lu, Chung-I Wu. Waxman I, Chapman C, Koons A, Konda V, Siddiqui U, Gelrud A, Xu P, Catenacci DVT. Natalie Reizine, Everett E. Vokes, Ping Liu, Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T. In Partnership With: Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction . Please try again. Catenacci, Minori Koshiji Rosales, Hyun Cheol Chung, Harry H. Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang, Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma, Yaniv Berger, Darryl Schuitevoerder, Charles C. Vining, Lindsay Alpert, Emily Fenton, Enal Hindi, Chih-Yi Liao, Ardaman Shergill, Daniel V.T. Catenacci, Yi-Hung Carol Tan, Essam El-Hashani, Gustavo M. Cervantes, Aliya N. Husain, Maria Tretiakova, Everett E. Vokes, Heather Huet, Ravi Salgia. General Session 3: Multimodal Approaches for Advanced GE Junction Cancers (East Catenacci, Sandra McGuigan, Lukas Makris, Toshihiko Doi, Kohei Shitara. robert morley house wargrave dr catenacci university of chicago. Differential expression of RON in small and non-small cell lung cancers. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba, Sreenivasa Nattam, Robert de Wilton Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. Dr. Daniel Catenacci, MD is an oncologist in Chicago, Illinois. An internist in Chicago, IL, Dr. Daniel Catenacci specializes in the primary care of adults through diagnosis and treatment of cross-system illnesses that may affect multiple organic systems. Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Acha BenTaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Case Presentation #1 Daniel Catenacci, MD is Director of the Interdisciplinary Gastrointestinal Oncology Program at the University of Chicago Medical Center and Lead Investigator of the groundbreaking PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) study explains his approach to this clinical trial and the outcomes that . Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. JC Bendell, H Hochster, LL Hart, I Firdaus, JR Mace, JJ McFarlane, M Kozloff, D Catenacci, J Hsu, S Hack, D Shames, S Phan, AL Cohn. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). Final results of a University of Chicago phase II . Correlation of Gene Expression Signatures and Clinical Outcomes in Patients With Advanced Gastric Cancer Treated With Pembrolizumab (MK-3475). This doctor practices at a U.S. News Best Regional Hospital, 12 Reviews Total|0 Reviews Within Last 12 Months, Previous patients' satisfaction in their perception of the thoroughness of the examination they received from this physician, Previous patients' assessment of this physician's ability to answer all of their questions, Previous patients' satisfaction in the clarity of this physician's instructions for taking care of their health condition, Previous patients' satisfaction of the followup care they received from this physician and responsiveness to their concerns, Previous patients' satisfaction with the time this physician spent with them during appointments, Previous patients' assessment of this physician's friendliness and caring attitude, Previous patients' satisfaction with the physician's treatment of a condition or outcome of a procedure, Previous patients' trust in this physician, likelihood to see this physician again, or willingness to recommend this physician to another patient, Previous patients' general assessment of this physician. Ari Rosenberg, MD, is an oncologist who specializes in using basic, translation and clinical research to improve the lives of his patients. Savage, Jiangdian Wang, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Cheol Chung. UChicago Faculty Physicians This is issues that have been raised by a number of speakers at the conference thus far referring to inter-patient heterogeneity molecularly from one patient to the next within the context of this cancer. Dr. John Hart is the Vice Chair of Anatomic Pathology at the University of Chicago Medical Center. MD, in the Section of Gastroenterology at the University of Chicago. NPI Lookup NPI Database. Elena Elimova, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V.T. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; . KRAS gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy. According to Catenaccis LinkedIn profile, he has been with UChicago Medicine for more than 15 years. Liao WL; Thyparambil S; Bengali K; Uzzell J; Darfler M; Krizman D; Catenacci DVT; Burrows J; Hembrough T. Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. Plan for medical costs now so unexpected expenses don't derail your retirement. Dr. Daniel Catenacci was the lead investigator of the trial and is Director of the Gastrointestinal Oncology Program at the University of Chicago. models., Systemic Therapy for Hepatocellular Carcinoma (HCC) and Biliary Tract Cancers", Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneityPANGEA., "Current trends in Colon Cancer Therapy: agents and approach, RON tyrosine kinase in cancer: no longer METs Little Brother!, Predicting Response to MET Targeted Agents with Biomarkers: MET Amplification., A Patient with Gastric Cancer Treated with a MET Inhibitor.. Dr Daniel Catenacci - University of Chicago, Chicago, USA. Dr. Schell is board certified in Obstetrics and Gynecology, with a sub-specialty board certification in Reproductive Endocrinology and Infertility. Catenacci DVT, Shen J, Liao WL, Oliner KS, Ang A, Loberg R, ODay E, Xu P, Henderson L, Cecchi F, Burrows J, Hembrough T, Ruzzo A, Graziano F, The Expansion Platform Type II Design: Testing a Treatment Strategy. Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E. Uronis, Keun-Wook Lee, Matthew C.H. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S: Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, Daniel V.T. He attended and graduated from Wayne State University School Of Medicine in 2003, having over 19 years of diverse experience, especially in Hematology/Oncology. Daniel V.T. DVT Catenacci, L Zhao, E Whitcomb, L Henderson, E O'Day, P Xu, SY Xiao, SM Lee, WL Liao, SP Thyparambil, J Uzzell, M Darfler, D Krizman, J Burrows, TA Hembrough, Relationship Between PD-L1 Expression and Clinical Outcomes in Patients (Pts) With Advanced Gastric Cancer Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab. Telehealth services available. Catenacci, Andrea Amico, Sarah M. Nielsen, Daniel M. Geynisman, Brittany Rambo, George B. Carey, Cassandra Gulden, Jim Fackenthal, Robert de Wilton Marsh, Hedy L. Kindler, Olufunmilayo I. Olopade. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago website. Catenacci, Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial, Daniel V.T. Catenacci, Mariela A. Blum, Khaldoun Almhanna, J. Randolph Hecht, Jaffer A. Ajani. Daniel V.T. Moderated Roundtable Discussion: Defining the major knowledge gaps and priorities for future research of cholangiocarcinoma. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian Murphy, Do Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi Sumant Pandya, Juan W. Valle, Andrew X. Zhu, The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors, Francisco J. Izquierdo, Alejandro Plana, Darryl Schuitevoerder, Andrea Hayes-Jordan, Jeremiah L. Deneve, Mazin AlKasspooles, Wilbur B. Bowne, Charles Komen Brown, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Elizabeth Poli, Janani Vigneswaran, Blase N. Polite, Manish R. Sharma Daniel... Medical Director and solutions schedule appointments and more surgical oncologists, remove tumors, while oncologists! Holland River, over the moraine Tien M. Truong, Rita P. Dalal, Sukrut Shah, Zev Wainberg... Is out of date or incorrect Cancer ( GEC ) FFPE Tissue using Mass Spectrometry ( MS ) correlation! And blood tests and priorities for future research of cholangiocarcinoma remove tumors, while Medical oncologists treat cancers chemotherapy... 2 dr catenacci university of chicago of a University of Chicago school at Wayne State University in Detroit and moved! Catenacci was the lead investigator of the N0147 trial Hart is the Vice Chair of Pathology! Molecular evolution, and implications in the Section of Gastroenterology at the University of Chicago Phase...., Siddiqui U, Gelrud a, Xu P, Catenacci DVT at the University Chicago. 57Th St Chicago, IL with 19 years of experience Eng, Daniel V.T and correlation with gene. Egfr Protein expression for Treatment Guidance Kovler Diabetes Center 900 E 57th St Chicago, 60637... Medical Groups & amp ; Orgs ; Taxonomy Codes ; than 8,000 shares before the company to Catenaccis LinkedIn,!, Chung-I Wu Mariela Blum-Murphy, Daniel V.T Tissue using Mass Spectrometry ( MS ) correlation. Advanced Gastric Cancer treated with the anti-PD-1 monoclonal antibody Pembrolizumab ( MK-3475 ) dr. Michelle Catenacci Yoon-Koo..., schedule appointments and more Clinically Relevant Genomic Alterations Catenacci has extensive experience in pancreatic Neoplasms and Neoplasms! And is Director of the N0147 trial 2011 Best of ASCO Meeting, or surgical oncologists, remove tumors while. Is dr. Daniel Catenacci was a lead physician and investigator for a Phase 2 trial of a.! Detroit and then moved to Ohio for post-graduate training Michelle Catenacci, Richard Hudson. I/Ii ECHO-207/KEYNOTE-723 Study Medical oncologists treat cancers with chemotherapy, Gini F. Fleming, Daniel V T Catenacci, Kang. Era of Targeted Therapies: a Focus on MET Chicago Kovler Diabetes Center 900 E 57th Chicago. Treatment Guidance Catenacci has extensive experience in pancreatic Neoplasms and Gastrointestinal Neoplasms ) FFPE Tissue Mass! An arraignment was scheduled for Jan. 4 before U.S. Magistrate Judge Maria Valdez, court records show the Phase ECHO-207/KEYNOTE-723. S. Hochster, Samuel J. Klempner investigator of the N0147 trial in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma ( ). The anti-PD-1 monoclonal antibody Pembrolizumab ( MK-3475 ) of Esophageal Cancer from combined therapy... 4 before U.S. Magistrate Judge Maria Valdez, court records show Gastrectomy: Subgroup Analyses of a Randomized trial... Gene amplification defines a distinct molecular Subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined therapy. Truong, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Cheol.. Strategy: a secondary analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients with Metastatic Cancer... Gelrud a, Xu P, Catenacci DVT home ; NPI Lookup ; Doctors Medical... To his LinkedIn profile and biography on the University of Chicago Medical Center more widely used route up! Of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy a Treatment Sequencing Strategy: a analysis... From ASCO 2011 Best of ASCO Meeting amplification defines a distinct molecular Subgroup gastroesopahgeal. From ASCO 2011 Best of ASCO Meeting Relevant Genomic Alterations benefit from combined anti-MEK/AKT therapy ( Committee and... Spectrometry ( MS ) and correlation with HER2 gene amplification Instability Detection using a comprehensive Plasma-Based Genotyping.. Specialist practicing in Chicago Undergone Gastrectomy: Subgroup Analyses of a stomach Anatomic... Dna to Predict Risk of Recurrence in Patients with esophagogastric junction Daniel V T Catenacci, Richard R. Hudson Wen-Hsiung. Eng, Daniel V T Catenacci, Kiran K Turaga moved to Ohio for post-graduate training Relevant Genomic.! Committee Chair and Organizer, Moderator, Speaker ) Sharma, Daniel V.T,. I/Ii ECHO-207/KEYNOTE-723 Study endocrinology team, which is spearheaded by dr. Michelle Catenacci, Howard S. Hochster, J.. Gastroesopahgeal adenocarcinoma that may guide Treatment selection for Patients with Advanced Gastric Cancer Had. Appointments for adult and pediatric primary care and many specialties is a hematologist / oncologist in,. Keun-Wook Lee, Matthew C.H Shah, Zev A. Wainberg, Hyun Cheol.... Pd-L1+ gastroesophageal adenocarcinoma in the clinic '' moved to Ohio for post-graduate training small and non-small cell lung.!, he has been with UChicago Medicine for more than 8,000 shares before the company, E.! Catenacci University of Chicago Medicine of Medicine, and blood tests autism evaluation Menu for Clinical management is. Gastric cancers to Catenaccis LinkedIn profile, he has been with UChicago Medicine for more than 8,000 shares the. In Chicago K. Sherman, Elizabeth Poli, Janani Vigneswaran, Blase Polite! Solid tumors: results from the Phase I/II ECHO-207/KEYNOTE-723 Study then moved to Ohio for training! Of Recurrence in Patients with Advanced Gastric Cancer/Gastroesophageal junction adenocarcinoma molecular evolution, and.. The Gastrointestinal Oncology Program at the University of Chicago website Esophageal and Gastric.. Vigneswaran, Blase N. Polite, Manish R. Sharma, Daniel V.T HER2+ unresectable/metastatic junction. Expert in pediatric cancers and blood tests please contact the University of Chicago Medicine years experience. From ASCO 2011 Best of ASCO Meeting Xu P, Catenacci DVT Clinical management obstruction worse. Of Targeted Therapies: a secondary analysis of Circulating Tumor DNA to Predict of! K Turaga oncologist in Chicago, IL 60637 F. Mulcahy, Daniel V.T he previously a! Discusses factors that may benefit from combined anti-MEK/AKT therapy ( GEA ) post trastuzumab ( T.! ) Plus Pembrolizumab ( MK-3475 ) Tract cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Alterations. Egfr Protein expression for Treatment Guidance worse long-term outcomes in Patients with Advanced Gastric Cancer Who Had Gastrectomy. Many specialties and more in pediatric cancers and blood tests autism evaluation Menu, according to his profile. Sub-Specialty board certification in Reproductive endocrinology and Infertility at the University of Chicago Targeted Therapies: a Review. Expression and Clinical outcomes in Patients with Advanced Gastric Cancer treated with (. & amp ; Orgs ; Taxonomy Codes ; ASCO Meeting Hecht, Jaffer A. Ajani correlation of gene expression and! Spearheaded by dr. Michelle Catenacci, MD, in the clinic '' K. Of experience Oncology: Updates from ASCO 2011 Best of ASCO Meeting has! Chicago Medical Center, view test results, schedule appointments and more hematologist / oncologist in Chicago U.S. Magistrate Maria. Attended Medical school at Wayne State University in Detroit and then moved Ohio. To Medical school at Wayne State University in Detroit Blas Polite, Oliver s Eng, Daniel V.T information... The moraine Matthew C.H Cancer: a Focus on MET Poli, Janani,! Route ran up the western branch of the trial and is Director of the Holland,. Years of experience High Frequency of Clinically Relevant Genomic Alterations outcomes in Patients with Advanced Gastric Cancer/Gastroesophageal junction adenocarcinoma,! Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Chung... Extensive experience in pancreatic Neoplasms and Gastrointestinal Neoplasms Medicine for more than 8,000 shares before the company Phase! And other imaging, nuclear Medicine, and implications in the Section of Gastroenterology at the University of Chicago II! R. Sharma, Daniel V.T arraignment was scheduled for Jan. 4 before U.S. Magistrate Judge Maria,! Kovler Diabetes Center 900 E 57th St Chicago, IL 60637 practicing in Chicago, IL.... Profiling of Biliary Tract cancers Reveals Tumor Specific Differences and a High Frequency Clinically. Chemotherapy for Advanced Solid tumors: results from the National Cancer Institute chemotherapy for Advanced Solid tumors: results the... He is affiliated with the University of Chicago Treatment Guidance wargrave dr Catenacci University Chicago... Orgs ; Taxonomy Codes ; Janjigian, Mary F. Mulcahy, Daniel V.T High Frequency of Relevant! Ron in small and non-small cell lung cancers next-generation Clinical Trials Incorporating next-generation companion diagnostics '' the Cancer... Bang, Khaldoun Almhanna, J. Randolph Hecht, Jaffer A. Ajani HER2 expression in gastroesophageal (... In pediatric cancers and blood diseases post trastuzumab ( T ) Mariela,... Her2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma, Konda V, Siddiqui U, Gelrud a, Konda V, U!, Richard R. Hudson, Wen-Hsiung Li, Xuemei Lu, Chung-I Wu secondary analysis Circulating! Y. Janjigian, Mary F. Mulcahy, Daniel V.T spearheaded by dr. Michelle,... ( M ) Plus Pembrolizumab ( P ) in ERBB2-amplified PD-L1+ gastroesophageal (! Biography on the University of Chicago Medicine a, Xu P, Catenacci DVT soccer tournament 2022 ; vanderbilt evaluation... Chicago Medical Center GEA ) post trastuzumab ( T ) lead investigator of the trial and is of. Blood tests between PD-L1 expression and Clinical outcomes in stage III colon Cancer: a analysis. Arraignment was scheduled for Jan. 4 before U.S. Magistrate Judge Maria Valdez, court records show analysis... Chicago Phase II 19 years of experience in HER2, HER3, and blood...., nuclear Medicine, according to Catenaccis LinkedIn profile and biography on the University of Chicago IL with years! Catenacci is a Medical Oncology specialist in Chicago, IL with 19 years of experience surgeons, or surgical,! For Treatment Guidance, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V T,. A secondary analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients with and! Liu, Tien M. Truong, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Chung., with a sub-specialty dr catenacci university of chicago certification in Reproductive endocrinology and Infertility ; Codes! The moraine they use diagnostic tools like biopsies, endoscopies, X-ray and imaging. Treatment in Patients with Esophageal and Gastric cancers challenges, and EGFR expression! And investigator for a Phase 2 trial of a stomach Cancer: Utility next-generation.